These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21097496)

  • 1. Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.
    Asano R; Ikoma K; Shimomura I; Taki S; Nakanishi T; Umetsu M; Kumagai I
    J Biol Chem; 2011 Jan; 286(3):1812-8. PubMed ID: 21097496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody.
    Asano R; Kumagai T; Nagai K; Taki S; Shimomura I; Arai K; Ogata H; Okada M; Hayasaka F; Sanada H; Nakanishi T; Karvonen T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    Protein Eng Des Sel; 2013 May; 26(5):359-67. PubMed ID: 23468569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody.
    Asano R; Ikoma K; Sone Y; Kawaguchi H; Taki S; Hayashi H; Nakanishi T; Umetsu M; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2010 Jul; 285(27):20844-9. PubMed ID: 20444691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
    Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
    J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
    Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
    Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528.
    Asano R; Sone Y; Ikoma K; Hayashi H; Nakanishi T; Umetsu M; Katayose Y; Unno M; Kudo T; Kumagai I
    Protein Eng Des Sel; 2008 Oct; 21(10):597-603. PubMed ID: 18621782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the Fc fusion format to generate tag-free bi-specific diabodies.
    Asano R; Ikoma K; Kawaguchi H; Ishiyama Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    FEBS J; 2010 Jan; 277(2):477-87. PubMed ID: 20015073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.
    Asano R; Kuroki Y; Honma S; Akabane M; Watanabe S; Mayuzumi S; Hiyamuta S; Kumagai I; Sode K
    MAbs; 2018; 10(6):854-863. PubMed ID: 29985753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
    Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.
    Kuwahara A; Nagai K; Nakanishi T; Kumagai I; Asano R
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Build-up functionalization of anti-EGFR × anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats.
    Asano R; Hosokawa K; Taki S; Konno S; Shimomura I; Ogata H; Okada M; Arai K; Onitsuka M; Omasa T; Nakanishi T; Umetsu M; Kumagai I
    Sci Rep; 2020 Mar; 10(1):4913. PubMed ID: 32188928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats.
    Fu MP; Guo ZL; Tang HL; Zhu HF; Shen GX; He Y; Lei P
    Curr Med Sci; 2020 Feb; 40(1):28-34. PubMed ID: 32166662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
    Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
    J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv.
    Korn T; Nettelbeck DM; Völkel T; Müller R; Kontermann RE
    J Gene Med; 2004 Jun; 6(6):642-51. PubMed ID: 15170735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.